ARCT · NASDAQ
Arcturus Therapeutics Holdings (ARCT) Stock Price & Fundamentals
Arcturus Therapeutics Holdings (ARCT) closed at $791.05 on Oct 9, 2026, down 1.13% from the previous close of $800.06.
Share price, past year
1Y +29.91%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $791.05 |
| Sep 30, 2026 | $805.70 |
| Aug 31, 2026 | $834.52 |
| Jul 31, 2026 | $798.10 |
| Jun 30, 2026 | $807.90 |
| May 29, 2026 | $801.82 |
| Apr 30, 2026 | $771.27 |
| Mar 31, 2026 | $707.07 |
| Feb 27, 2026 | $605.58 |
| Jan 30, 2026 | $627.47 |
| Dec 31, 2025 | $620.39 |
| Nov 28, 2025 | $605.00 |
| Oct 31, 2025 | $622.15 |
Key statistics
- Market cap
- $22.48B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.33
- Revenue (TTM)
- $29.37M
- Net income (TTM)
- −$93.28M
- Shares outstanding
- 28.4M
- Dividend yield
- —
- 52-week range
- $594.82 – $839.64
Arcturus Therapeutics Holdings's market cap is $22.48B, based on a share price of $791.05 and 28.4M shares outstanding as of Jun 30, 2026.
Financials
Arcturus Therapeutics Holdings reported revenue of $82.03M for fiscal 2025, down 46.14% from fiscal 2024.
Arcturus Therapeutics Holdings reported a net loss of $65.78M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $82.03M | −46.1% | −$65.78M | −80.2% | −$2.40 | −$74.50M |
| FY2024ended Dec 31, 2024 | $152.31M | −8.7% | −$80.94M | −53.1% | −$3.00 | −$60.40M |
| FY2023ended Dec 31, 2023 | $166.80M | −19.0% | −$29.73M | −17.8% | −$1.12 | −$21.00M |
| FY2022ended Dec 31, 2022 | $206.00M | +1,566.8% | $9.35M | 4.5% | $0.35 | $24.27M |
| FY2021ended Dec 31, 2021 | $12.36M | +29.6% | −$203.67M | −1,648.0% | −$7.74 | −$138.45M |
| FY2020ended Dec 31, 2020 | $9.54M | −54.1% | −$72.15M | −756.4% | −$3.55 | −$44.60M |
| FY2019ended Dec 31, 2019 | $20.79M | +32.0% | −$25.99M | −125.0% | −$2.15 | −$7.26M |
| FY2018ended Dec 31, 2018 | $15.75M | — | −$21.79M | −138.3% | −$2.16 | −$22.24M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $2.96M | −$23.79M | −$0.84 |
| Q1 FY2026ended Mar 31, 2026 | $2.06M | −$26.96M | −$0.95 |
| Q4 FY2025ended Dec 31, 2025 | $7.20M | −$29.08M | −$1.05 |
| Q3 FY2025ended Sep 30, 2025 | $17.15M | −$13.45M | −$0.49 |
| Q2 FY2025ended Jun 30, 2025 | $28.30M | −$9.18M | −$0.34 |
| Q1 FY2025ended Mar 31, 2025 | $29.38M | −$14.08M | −$0.52 |
| Q4 FY2024ended Dec 31, 2024 | $22.77M | −$30.01M | −$1.10 |
| Q3 FY2024ended Sep 30, 2024 | $41.67M | −$6.90M | −$0.26 |
Company profile
- Name
- Arcturus Therapeutics Holdings Inc.
- Ticker
- ARCT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10285 Science Center Drive, San Diego, CA
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001768224
Recent SEC filings
- Sep 23, 2026
- Aug 25, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 2, 2026
- Jun 5, 2026
- May 7, 2026
- May 7, 2026
Frequently asked questions
What is Arcturus Therapeutics Holdings's stock price?
Arcturus Therapeutics Holdings (ARCT) closed at $791.05 on Oct 9, 2026, down 1.13% from the previous close of $800.06.
What is Arcturus Therapeutics Holdings's market cap?
Arcturus Therapeutics Holdings's market cap is $22.48B, based on a share price of $791.05 and 28.4M shares outstanding as of Jun 30, 2026.
How much revenue does Arcturus Therapeutics Holdings make?
Arcturus Therapeutics Holdings reported revenue of $82.03M for fiscal 2025, down 46.14% from fiscal 2024.
Does Arcturus Therapeutics Holdings pay a dividend?
Arcturus Therapeutics Holdings's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Arcturus Therapeutics Holdings Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures